Prospective molecular profiling of canine cancers provides a clinically relevant comparative model for evaluating personalized medicine (PMed) trials.

PubWeight™: 0.83‹?›

🔗 View Article (PMC 3956546)

Published in PLoS One on March 17, 2014

Authors

Melissa Paoloni1, Craig Webb2, Christina Mazcko1, David Cherba2, William Hendricks3, Susan Lana4, E J Ehrhart4, Brad Charles4, Heather Fehling5, Leena Kumar5, David Vail6, Michael Henson7, Michael Childress8, Barbara Kitchell9, Christopher Kingsley3, Seungchan Kim3, Mark Neff2, Barbara Davis3, Chand Khanna1, Jeffrey Trent10

Author Affiliations

1: Comparative Oncology Program, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, United States of America.
2: Van Andel Research Institute, Grand Rapids, Michigan, United States of America.
3: Translational Genomics Research Institute (TGen), Phoenix, Arizona, United States of America.
4: Colorado State University, College of Veterinary Medicine, Fort Collins, Colorado, United States of America.
5: Clinical Reference Laboratory, Lenexa, Kansas, United States of America.
6: University of Wisconsin-Madison, School of Veterinary Medicine, Madison, Wisconsin, United States of America.
7: University of Minnesota, College of Veterinary Medicine, St. Paul, Minnesota, United States of America.
8: Purdue University, School of Veterinary Medicine, West Lafayette, Indiana, United States of America.
9: Michigan State University, College of Veterinary Medicine, East Lansing, Michigan, United States of America.
10: Van Andel Research Institute, Grand Rapids, Michigan, United States of America; Translational Genomics Research Institute (TGen), Phoenix, Arizona, United States of America.

Articles cited by this

The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99

Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature (2005) 23.04

How many drug targets are there? Nat Rev Drug Discov (2006) 14.22

DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res (2010) 13.68

Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A (2001) 7.51

Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol (2010) 6.34

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood (2002) 4.00

A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci U S A (2007) 3.78

Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer (2008) 3.23

Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res (2012) 3.14

Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest (2000) 2.70

Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biol (2010) 2.60

Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. J Intern Med (2012) 2.13

The dog as a cancer model. Nat Biotechnol (2006) 2.08

Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities. Mol Cancer Ther (2012) 1.72

Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Cancer Res (2007) 1.66

Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics (2009) 1.57

Identifying disease-specific genes based on their topological significance in protein networks. BMC Syst Biol (2009) 1.54

Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature. PLoS One (2009) 1.33

Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs (2002) 1.18

Gene profiling of canine B-cell lymphoma reveals germinal center and postgerminal center subtypes with different survival times, modeling human DLBCL. Cancer Res (2013) 1.14

What are we learning from the cancer genome? Nat Rev Clin Oncol (2012) 1.13

How comparative effectiveness research can help advance 'personalized medicine' in cancer treatment. Health Aff (Millwood) (2011) 1.11

Molecular profiling of cancer--the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic. Semin Oncol (2011) 1.05

Molecular diagnostics and personalized medicine in oncology: challenges and opportunities. J Cell Biochem (2013) 1.04

A compendium of canine normal tissue gene expression. PLoS One (2011) 0.97

Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma. Cancer Biol Ther (2009) 0.96

Rapamycin pharmacokinetic and pharmacodynamic relationships in osteosarcoma: a comparative oncology study in dogs. PLoS One (2010) 0.92

Mouse models of cancers: opportunities to address heterogeneity of human cancer and evaluate therapeutic strategies. J Mol Med (Berl) (2010) 0.92

Personalized medicine in oncology: a personal view with myths and facts. Curr Clin Pharmacol (2010) 0.81

Clinical cancer genome and precision medicine. Ann Surg Oncol (2012) 0.80

Gene expression significance in personalized medicine of non-small-cell lung cancer and gene expression analyzing platforms. Curr Drug Metab (2011) 0.80

A multi-site feasibility study for personalized medicine in canines with osteosarcoma. J Transl Med (2013) 0.79